IQVIA (IQV)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$203.90-2.08%
Close 2026-07-08 · 1-day change
Reading IQV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IQV free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IQV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IQV free→QuarterlyIQ Insights · IQV
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $203.90. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $208 IQV trades at 19× p/e, below its 35× p/e peer median. Our $249 fair value sits above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $185–$249. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $217.50 | — | — | Analyst | high |
| dcf fcfe | 12M | $214.63 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $201.43 | — | — | Hist. CAGR | high |
| graham number | 12M | $95.59 | — | — | TTM | high |
| Mgmt guidance |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$185.00 – $249.00 (median $217.50) · 6 analysts · as of 2026-07-06
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 1% over what the business is worth with no growth; closing that gap needs roughly 1.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $10.93/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $436.33 |
| 34.4 |
| 12.70 |
| Mgmt |
| high |
| Peer EV/EBITDA | 12M | $201.89 | 15.1 | 18.75 | TTM | high |
| Peer P/FCF | 12M | $353.28 | 30.6 | 11.54 | TTM | high |
| Peer P/E | 12M | $425.34 | 34.4 | 12.38 | TTM | high |
| Peer P/S | 12M | $347.30 | 3.5 | 97.95 | TTM | high |
| PEG | 12M | $677.59 | 54.7 | 12.38 | TTM | high |
| residual income | 12M | $64.24 | — | — | TTM | high |
| Own P/E history | 12M | $236.66 | 19.1 | 12.38 | TTM | high |
| triangulated | 12M | $374.64 | 34.4 | 10.90 | Triangulated | high |
| Mgmt guidance | 3Y | $750.29 | 34.4 | 21.84 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $458.94 | 30.6 | 14.99 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $516.70 | 34.4 | 15.04 | Analyst | medium |
| Peer P/S | 3Y | $404.47 | 3.5 | 114.07 | guidance | medium |
| PEG | 3Y | $823.13 | 54.7 | 15.04 | Analyst | medium |
| Own P/E history | 3Y | $287.49 | 19.1 | 15.04 | Analyst | medium |
| Mgmt guidance | 5Y | $1076.88 | 34.4 | 31.34 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $546.40 | 30.6 | 17.84 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $555.81 | 34.4 | 16.18 | Analyst | high |
| Peer P/S | 5Y | $435.09 | 3.5 | 122.71 | guidance | high |
| PEG | 5Y | $885.44 | 54.7 | 16.18 | Analyst | high |
| Own P/E history | 5Y | $309.25 | 19.1 | 16.18 | Analyst | high |